Nick Galakatos

Spear's Review

When the Blackstone Group observed that pharmaceutical companies faced severe pressures, it worried that key medical research might be severely thwarted.

The New York asset manager, which in 2018 already managed more than £337 billion, made an effort to bulk up its investments in healthcare by acquiring Clarus, a leading global life sciences investment firm. 

Nick Galakatos, who co-founded Clarus, now acts as the global head of life sciences at Blackstone Life Sciences, with over 30 years of experience in the healthcare and finance sectors. He has led investments in biotechnology, pharmaceutical company partnerships and diagnostics, from start-ups to commercial-stage companies.